KRAS and lung carcinoma: Indeed, one in four human cancers contain mutant forms of RAS, with substitutions frequently observed in pancreatic cancer (∼88% K-RAS mutation positive), colon cancer (∼50% K-RAS), lung cancer (∼32% K-RAS) and melanoma (∼17% N-RAS) (Prior et al., 2020).